Clinical Trial

A Real-World Study of Neoadjuvant/Conversion Therapy for Colorectal Cancer With Chemotherapy And Anti-Angiogenic Targeted Agents

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated June 24, 2024 (before its estimated April 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
Fruquintinib is already the standard third-line treatment for metastatic colorectal cancer, but the efficacy of fruquintinib in neoadjuvant and conversion therapy for locally advanced/advanced colorectal cancer has not yet been reported. This study aims to observe the efficacy and safety of fruquintinib combined with chemotherapy in neoadjuvant or conversion therapy for colorectal cancer patients in the real world.
Trial Details
NCT Number NCT06470178
Lead Sponsor Wuhan University
Conditions Colorectal Cancer
Enrollment 70 participants
Start Date 2025-05-01
Primary Completion 2026-04-30 (estimated)
Study Completion 2027-04-30 (estimated)
Updated on ClinicalTrials.gov 2024-06-24